Specialty Equity Research and Professional Trading Service

Trades fully vetted with in-depth research based on a 3-pronged approach:
Fundamentals, Technicals and Options Activity

Jaguar 30 Long/Short Index | $83.43 (+1.72%)


Welcome  Jags!

Our mission is to deliver actionable, timely, fundamentally driven equity research to help you outperform the broader market. Our trading is based on a specific, tried-and-true approach that consistently delivers results. Read more about our methods.

You will receive top of the line research and market information, along with specific trade recommendations. Check out the subscription page for more details, and please read a welcome letter from Fahad Khalid, Chief Executive Officer.

For more research notes like these, sign-up for our free weekly newsletter, JaguarResearch.

July 10, 2020 | 10:38 AM by Jaguar

UroGen Pharma (URGN) – Urothelial Carcinoma

Incorporated in Israel with corporate office in New Jersey, UroGen Pharma (URGN) is a biopharmaceutical company that very recently received FDA approval for its first marketable treatment. The company also…

Continue Reading »

July 7, 2020 | 11:29 AM by Jay Kunstman

CytoSorbents (CTSO) – Prepared for the Storm

CytoSorbents is an immunotherapy company specializing in blood purification to control or reduce deadly inflammation in critically-ill and cardiac surgery patients. Its main product is CytoSorb, which is designed to…

Continue Reading »

June 22, 2020 | 1:53 PM by Jay Kunstman

Industry Checks – Golf (DKS, ELY, GOLF)

In yesterday’s W/E Research, Garmin (GRMN) was presented with a bullish view after spotting recent app download checks that were positive across all different segments, from Health & Fitness, to…

Continue Reading »

June 15, 2020 | 11:39 PM by Jay Kunstman

ADA 2020 Commentary (DXCM, MDT, PODD, TNDM)

In case you missed it after the close today, Abbott Laboratories (ABT) was covered HERE following their appearance at the American Diabetes Association Conference. In addition to ABT, I thought…

Continue Reading »

June 12, 2020 | 11:45 AM by Jay Kunstman

Catalyst Watch – BioSpecifics Technologies (BSTC)

Biotech company BioSpecifics Technologies develops collagenase-based based therapies in the United States and internationally. It has developed a first-in-class collagenase-based product “Collagenase Clostridium Histolyticum (CCH)” marketed in the U.S. as…

Continue Reading »

Read more articles
Sign up for a four-week trial!

Password must meet the following requirements: